Market Overview

UPDATE: Jefferies Downgrades Regeneron Pharmaceuticals to Hold on Limited Eylea Upside

Share:
Related REGN
The Other Bearish Biotech ETF Is Looking Groovy, Too
What Are Payors Saying About Managed Care Giants?
FDA OKs Cholesterol Drug (Investor's Business Daily)

Jefferies downgraded Regeneron Pharmaceuticals (NASDAQ: REGN) from Buy to Hold and maintained a $179.00 price target.

Jefferies noted, "We conducted another wAMD survey which predicts limited near/mid-term upside to Eylea sales over our ests and current valuation which already reflect anticipated growth. Notably, benefit from potential cmpding driven decline in Avastin use only modestly benefits Eylea. … Following REGN's Jan 8 pre- announcement of U.S. Eylea sales of $838M for Q4 2012 with FY2013 guidance of $1.2-$1.3B and based on our survey results, we increased our U.S. Eylea wAMD sales incrementally by 1-2% for 2013-17, modestly impacting the topline."

Regeneron Pharmaceuticals closed at $179.40 on Monday.

Latest Ratings for REGN

DateFirmActionFromTo
Aug 2015BarclaysMaintainsEqual-weight
Aug 2015Brean CapitalMaintainsBuy
Aug 2015Morgan StanleyMaintainsOverweight

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (REGN)

Get Benzinga's Newsletters